&nbsp;

Aug 2023

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

arsenic trioxide

Other Name(s): Trisenox®

Quick Link(s):

Oct 2023

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Regimen

AZCT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML),

Myelodysplastic Syndrome (MDS),

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts

Drugs Used:

azaCITIDine

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

regorafenib (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours,

Sarcoma,

GIST

Intent: Palliative

Funding:

Exceptional Access Program

Drugs Used:

regorafenib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

ALEM+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

alemtuzumab (Compassionate),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

RAMU

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Drugs Used:

ramucirumab (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria

Drugs Used:

regorafenib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab